Technology

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Published

2 months ago

July 19, 2024

BEIJING, July 19, 2024 /PRNewswire/ — CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:

https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htm

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company’s China-based regulatory and commercial competencies and its global drug development expertise. The Company’s operations in China are conducted through its wholly owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. More information on CASI is available at www.casipharmaceuticals.com.

CASI Forward-Looking Statements:

This announcement and the current report on Form 6-K contain forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the business outlook and quotations from management in this announcement and the current report on Form 6-K, as well as the Company’s strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on The Nasdaq Capital Market if we fail to satisfy applicable continued listing standards; the volatility in the market price of our ordinary shares; the risk of substantial dilution of existing shareholders in future share issuances; the difficulty of executing our business strategy on a global basis including China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; legal or regulatory developments in China that adversely affect our ability to operate in China, our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency, PRC National Medical Products Administration, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the risks associated with our product candidates, and the risks associated with our other early-stage products under development; the risk that result in preclinical and clinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; our ability to protect our intellectual property rights; the lack of success in the clinical development of any of our products; and our dependence on third parties; the risks related to our dependence on Juventas to conduct the clinical development of CNCT19 and to partner with us to co-market CNCT19; risks related to our dependence on Juventas to ensure the patent protection and prosecution for CNCT19; risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); risks relating to interests of our largest shareholder and our Chairman and CEO that differ from our other shareholders; and risks related to the development of a new manufacturing facility by CASI Pharmaceuticals (Wuxi) Co., Ltd. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided herein is as of the date of this announcement and the current report on Form 6-K, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

EVOMELA® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN® is proprietary to Acrotech Biopharma Inc and its affiliates.

COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-reports-development-relating-to-its-disputes-with-juventas-302201852.html

SOURCE CASI Pharmaceuticals, Inc.

Technology

Expo enhanced by China-ASEAN cooperation

Published

55 mins ago

September 27, 2024

BEIJING, Sept. 27, 2024 /PRNewswire/ — A report from China Daily:

The 21st China-ASEAN Expo, which is taking place in Nanning, Guangxi Zhuang autonomous region, aims to increase consensus, deepen mutually beneficial cooperation, and enhance China-ASEAN collaboration to an unparalleled level.

The expo, which commenced on Tuesday and will run until Saturday, is marked by several new initiatives. Notably, it provides a novel theme focusing on strategic emerging industries, spotlighting cutting-edge advancements and technological breakthroughs in such areas as digital technology, green low-carbon initiatives, new energy and smart connected vehicles.

Moreover, the expo introduces a high-tech product exhibition area tailored for ASEAN countries, a first-time feature that showcases technical progress made in healthcare, information technology, new energy and other key sectors. It aims to support high-tech ASEAN enterprises in expanding their market presence in China and beyond.

The 21st CAEXPO is to include an open day, offering businesses enhanced market visibility and granting the general public a firsthand experience of the concrete outcomes resulting from practical cooperation between China and ASEAN countries.

This year’s expo boasts an exhibition area spanning nearly 200,000 square meters and has attracted the participation of more than 3,000 companies, with Malaysia taking the spotlight as the “theme country”.

Malaysian government officials are set to participate in dialogues with Chinese enterprise CEOs, fostering better understanding of the country’s investment policies and aiding the exploration of overseas markets.

At the 21st CAEXPO, the United Arab Emirates has confirmed its participation as a “special partner country”, marking a historic moment as it becomes the first Gulf Cooperation Council member to attend.

The UAE has established a national pavilion to display its investment environment, key industries and cooperative projects, promoting direct dialogue and partnerships between enterprises.

Through extensive discussions, they will collaborate on trade, tourism, investment, finance, and technology, jointly develop new areas and partnership frameworks to strengthen the bilateral economic and trade ties.

The expo also features a dedicated China-ASEAN cultural exchange exhibition zone, highlighting examples and collaborative accomplishments in this field.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/expo-enhanced-by-china-asean-cooperation-302260938.html

SOURCE China Daily

Technology

Huawei Unveils the Xinghe Intelligent Autonomous Driving Network Solution, Accelerating Digital and Intelligent Transformations Across Industries

Published

55 mins ago

September 27, 2024

SHANGHAI, Sept. 27, 2024 /PRNewswire/ — At HUAWEI CONNECT 2024, the “Xinghe Intelligent Autonomous Driving Network” session successfully brought together over 100 representatives from enterprises, industry experts, and partners. During this session, Huawei introduced the industry’s first L4 autonomous driving network solution — Xinghe Intelligent Autonomous Driving Network, paving the way for comprehensive digital and intelligent transformations across various sectors.

As AI technologies reach critical milestones and AI applications approach a tipping point, industries are increasingly adopting AI solutions. Also, the rapid advancement of computing power has led to the widespread implementation of digital twins and various large language models (LLMs), driving network intelligence into a new phase of rapid development. The integration of these new technologies into the network domain is becoming inevitable.

To address these advancements, Huawei launched the Xinghe Intelligent Autonomous Driving Network solution for enterprises. Wang Hui, President of NCE Domain at Huawei Data Communication Product Line, emphasized that the solution features a three-layer architecture comprising intelligent network elements (NEs), digital twins, and an intelligent brain. It integrates foundational capabilities, including the 10B-level-corpus telecom foundation model and cloud-map algorithm powered simulations, to create an L4 autonomous driving network capable of self-identifying risks, autonomously resolving faults, and self-verifying changes. This solution offers an AI-assisted O&M expert designed for various industries, including finance and education.

Intelligent NEs: These NEs can sense comprehensive data — including services, traffic, and applications — within milliseconds, providing essential data for network-wide intelligence and significantly enhancing the processing efficiency of underlying network devices.Digital twins: The network digital map creates a multi-dimensional, real-time visualization of the network, allowing for online simulations. It offers a lightweight operations and maintenance (O&M) solution that facilitates trial and error, accelerating the innovative iteration of network operations.Intelligent brain: Utilizing the telecom foundation model, this component accurately interprets user intentions through natural language, transforms user requirements, and dynamically invokes various scenario-based AI agents, achieving end-to-end network intelligence.

As AI model technologies continue to evolve and deepen in application, Huawei remains committed to ongoing research and development, striving for more precise intelligent decision-making and efficient automated management across various scenarios, ultimately helping customers’ networks advance towards L4 high-level intelligence.

Photo – https://mma.prnewswire.com/media/2517493/image_5009699_30809477.jpg

View original content:https://www.prnewswire.co.uk/news-releases/huawei-unveils-the-xinghe-intelligent-autonomous-driving-network-solution-accelerating-digital-and-intelligent-transformations-across-industries-302260942.html

Technology

China Arbitration Summit 2024 and China-MENA Arbitration Summit Held in Beijing

Published

55 mins ago

September 27, 2024

BEIJING, Sept. 27, 2024 /PRNewswire/ — The China Arbitration Summit 2024 and China-MENA Arbitration Summit was successfully held in Beijing on September 26, under the theme “International Arbitration Transcending Eras.” Nearly 500 attendees from 47 countries and regions, including government officials, leaders from international organizations, and representatives from major arbitration institutions, judges, arbitrators, lawyers, scholars, and business professionals, participated in the event.

The forum achieved practical results, contributing to strengthening legal cooperation, advancing international arbitration, and supporting the global economic order.

Ren Hongbin, Chairman of the China Council for the Promotion of International Trade (CCPIT) and the China International Economic and Trade Arbitration Commission (CIETAC), highlighted that CIETAC has solidified China’s leading position in arbitration. He emphasized that CIETAC aims to contribute further to high-quality international arbitration development, global economic recovery, and the building of a shared future for humanity.

Li Mingzheng, Vice Minister of Justice of China, stated that CIETAC’s independent, fair, and efficient arbitration services are widely recognized domestically and internationally. He emphasized the need for continuous innovation in arbitration, further development of rules, and enhanced international collaboration to build a global brand for arbitration services.

Wang Shumei, a senior justice and member of the Supreme People’s Court of China, shared measures taken by Chinese courts to innovate in arbitration and improve their role in global governance. She affirmed that Chinese courts will continue to foster a favorable legal environment for the advancement of international arbitration.

In a video message, Anna Joubin-Bret, Secretary-General of the United Nations Commission on International Trade Law (UNCITRAL), reaffirmed UNCITRAL’s commitment to addressing the new opportunities and challenges posed by modern dispute resolution.

Ismail Selim, President of the International Federation of Commercial Arbitration Institutions (IFCAI), stressed that arbitration must evolve to align with the era’s trends of digitization and interconnectedness, promoting shared vision, adaptability, inclusivity, and global integration.

The forum saw the launch of the “2024 International Arbitration Cooperation Initiative”, led by CIETAC and supported by arbitration institutions primarily from the Middle East and North Africa. The initiative aims to enhance cooperation among international arbitration bodies and contribute to building a community of shared future through arbitration.

CIETAC signed cooperation agreements with six international arbitration and legal service institutions, establishing mechanisms for joint research projects, co-hosted training, mutual recommendations of arbitrators, and shared use of facilities.

The summit was organized by Guangxi CA Panorama Group.

Photo – https://mma.prnewswire.com/media/2517341/The_forum_saw_the_launch_of_the__2024_International_Arbitration_Cooperation_Initiative.jpg

View original content:https://www.prnewswire.co.uk/news-releases/china-arbitration-summit-2024-and-china-mena-arbitration-summit-held-in-beijing-302260946.html